Literature DB >> 9459152

Expression and degeneration of tenascin-C in human lung cancers.

H Kusagawa1, K Onoda, S Namikawa, I Yada, A Okada, T Yoshida, T Sakakura.   

Abstract

Tenascin-C is an extracellular matrix glycoprotein produced in response to epithelial-mesenchymal interactions during organogenesis and tissue remodelling. It has therefore been proposed as a stromal marker for epithelial malignancy. To test this hypothesis, 30 human lung cancers, presenting a variety of clinicopathological features, and six specimens of normal tissue were examined by Western and Northern blotting of tenascin-C protein and mRNA. The results obtained were: (1) elevated tenascin-C expression was detected in all 30 cases by Western blotting, with mRNA increase in 22 of them; (2) mRNA for a large isoform of tenascin-C, including an alternatively spliced sequence, was expressed in lung cancer tissues but not in normal lungs; and (3) metastasis to lymph nodes was frequently found in cases whose tenascin-C was degraded into small fragments. These results suggest that tenascin-C degradation can be used as a marker for metastatic potential of a tumour.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459152      PMCID: PMC2151247          DOI: 10.1038/bjc.1998.15

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohistochemical study.

Authors:  P Van Eyken; R Sciot; V J Desmet
Journal:  J Hepatol       Date:  1990-07       Impact factor: 25.083

2.  Isolation and characterization of human fibroblast tenascin. An extracellular matrix glycoprotein of interest for developmental studies.

Authors:  Y Oike; H Hiraiwa; H Kawakatsu; M Nishikai; T Okinaka; T Suzuki; A Okada; R Yatani; T Sakakura
Journal:  Int J Dev Biol       Date:  1990-06       Impact factor: 2.203

3.  Tenascin is a stromal marker for epithelial malignancy in the mammary gland.

Authors:  E J Mackie; R Chiquet-Ehrismann; C A Pearson; Y Inaguma; K Taya; Y Kawarada; T Sakakura
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 4.  Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors.

Authors:  H P Erickson; M A Bourdon
Journal:  Annu Rev Cell Biol       Date:  1989

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose.

Authors:  J Kyhse-Andersen
Journal:  J Biochem Biophys Methods       Date:  1984-12

8.  Tenascin expression in the human endometrium and in endometrial adenocarcinomas.

Authors:  G Vollmer; G P Siegal; R Chiquet-Ehrismann; V A Lightner; H Arnholdt; R Knuppen
Journal:  Lab Invest       Date:  1990-06       Impact factor: 5.662

9.  The distribution of immuno-reactive tenascin in the epithelial-mesenchymal junctional areas of benign and malignant squamous epithelia.

Authors:  R Anbazhagan; T Sakakura; B A Gusterson
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1990

10.  Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.

Authors:  M A Bourdon; C J Wikstrand; H Furthmayr; T J Matthews; D D Bigner
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

View more
  8 in total

1.  The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Authors:  Chiara Catania; Michela Maur; Rossana Berardi; Andrea Rocca; Anna Maria Di Giacomo; Gianluca Spitaleri; Cristina Masini; Chiara Pierantoni; Reinerio González-Iglesias; Giulia Zigon; Annaelisa Tasciotti; Leonardo Giovannoni; Valeria Lovato; Giuliano Elia; Hans D Menssen; Dario Neri; Stefano Cascinu; Pier Franco Conte; Filippo de Braud
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

2.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

Review 3.  Revisiting the Tenascins: Exploitable as Cancer Targets?

Authors:  Richard P Tucker; Martin Degen
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

4.  Clinical significance of serum tenascin-C levels in breast cancer.

Authors:  D Tastekin; F Tas; S Karabulut; D Duranyildiz; M Serilmez; M Guveli; S Vatansever
Journal:  Tumour Biol       Date:  2014-04-03

Review 5.  Tenascin C in metastasis: A view from the invasive front.

Authors:  Camille M Lowy; Thordur Oskarsson
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

6.  Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.

Authors:  Florian Gebauer; Suyin Gelis; Hilke Zander; Karl-Frederick Meyer; Gerrit Wolters-Eisfeld; Jakob R Izbicki; Maximilian Bockhorn; Michael Tachezy
Journal:  Oncotarget       Date:  2016-04-12

Review 7.  The Functional Role of Extracellular Matrix Proteins in Cancer.

Authors:  Nadezhda V Popova; Manfred Jücker
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

Review 8.  Tenascin-C: Form versus function.

Authors:  Sean P Giblin; Kim S Midwood
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.